通化東寶(600867.SH)增加經營範圍 涉及甘精胰島素
格隆匯12月11日丨通化東寶(600867.SH)公佈,公司於2019年12月11日召開的第九屆董事會第二十四次會議,審議通過了《關於增加經營範圍並修改公司章程的議案》。因公司甘精胰島素注射液已獲得由國家藥品監督管理局核准簽發的《藥品註冊批件》,故增加經營範圍並對《公司章程》進行修改。
修訂前條款內容,第十三條經公司登記機關核准,公司經營範圍是:硬膠囊劑、片劑(含激素類)、顆粒劑、小容量注射劑、原料藥(重組人胰島素)、生物工程產品(重組人胰島素注射劑)、II類6854手術室、急救室、診療設備及器具、II類6815注射穿刺器械、III類6815注射穿刺器械、II類:6840臨牀檢驗分析儀器及診斷試劑(含診斷試劑);6841醫用化驗和基礎設備器具。
修訂後條款內容,第十三條經公司登記機關核准,公司經營範圍是:硬膠囊劑、片劑(含激素類)、顆粒劑、小容量注射劑、原料藥(重組人胰島素、甘精胰島素)、生物工程產品(重組人胰島素注射劑、甘精胰島素注射液)、II類6854手術室、急救室、診療設備及器具、II類6815注射穿刺器械、III類6815注射穿刺器械、II類:6840臨牀檢驗分析儀器及診斷試劑(含診斷試劑);6841醫用化驗和基礎設備器具。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.